Suraksha Diagnostic Limited — Board Meeting, 27-03-2025: Outcome of Board Meeting

Suraksha Diagnostic Limited has announced a board meeting outcome where the Board approved a strategic investment not exceeding ₹5.19 crore in Fetomat Wellness Private Limited, representing a 63% stake. The investment will occur through a Share Subscription Agreement for 95,841 equity shares and Share Purchase Agreements for 2,77,582 equity shares, making Fetomat a subsidiary. This acquisition is anticipated to enhance Suraksha’s service portfolio by integrating fetal medicine expertise and strengthening its market position. The transaction completion is expected within three months, subject to customary conditions.